Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Long-Term Investments (2022 - 2025)

Historic Long-Term Investments for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Q3 2025 value amounting to $3.0 million.

  • Tarsus Pharmaceuticals' Long-Term Investments changed 0.0% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $3.0 million for FY2024, which is 37543.58% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Long-Term Investments stood at $3.0 million, which was down 0.0% from $3.0 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Long-Term Investments' 5-year high stood at $3.0 million during Q2 2024, with a 5-year trough of $157000.0 in Q3 2022.
  • Moreover, its 4-year median value for Long-Term Investments was $631000.0 (2023), whereas its average is $1.6 million.
  • In the last 5 years, Tarsus Pharmaceuticals' Long-Term Investments skyrocketed by 132857.14% in 2024 and then changed by 0.0% in 2025.
  • Quarter analysis of 4 years shows Tarsus Pharmaceuticals' Long-Term Investments stood at $371000.0 in 2022, then soared by 70.08% to $631000.0 in 2023, then skyrocketed by 375.44% to $3.0 million in 2024, then changed by 0.0% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $3.0 million for Q2 2025, and $3.0 million during Q1 2025.